←Chronic Pain
Study register · detail Real-World-Beobachtungsstudie (Patient-Reported Outcomes) · Chronic Pain · 2023

„Patient-reported outcomes“ bei chronischen Erkrankungen unter Therapie mit Cannabisarzneimitteln

Gastmeier et al. ·Der Schmerz Impact 0.6
Clear benefit GRADE Low 1 citations
Samplen = 1.030 Pat.
Duration15 weeks
EndpointQuality of life
Blindingn.a.
DesignReal-World-Beobachtungsstudie (Patient-Reported Outcomes)
Key finding

In 84% of participants, quality of life improved markedly under cannabis medicine therapy according to subjective assessment.

Summary

Real-world registry on cannabis therapy in chronically ill patients in Germany (n=1.030); pain was the most common symptom (71%), followed by sleep disturbances (64%). Subjective quality of life improvement in 84% of patients. Symptom matrix (SMX) of 6 core symptoms identified.

P
PopulationChronically ill adults under physician-prescribed cannabis medicine therapy in Germany, n=1030 (fully analyzed datasets from 1582 participants)
I
InterventionCannabis medicines (CAM), physician-prescribed, various indications (dosage and route of administration not specified)
O
OutcomeQuality of life improvement in 84% of participants according to subjective assessment; most common symptoms: pain (71%), sleep disturbance (64%), stress/tension (52%), inner restlessness (52%), depressive mood (44%), muscle tension (43%)
Confidence in the evidence
Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Gastmeier K, Ihlenfeld A, Gastmeier A, Hirt G, Landschaft A, Wirz S
DOI 10.1007/s00482-024-00802-4↗
Design: Real-World-Beobachtungsstudie (Patient-Reported Outcomes)
Share
Indication
Further studies on Chronic Pain
All studies →
S Hjorthøj et al. · 2022 · European Journal of Pain
12 citations
Cannabis-based medicines and medical cannabis for patients with neuropathic pain and other pain disorders: Nationwide register-based pharmacoepidemiologic comparison with propensity score matched controls
Mixed Cochrane Review

Cochrane SR über cannabisbasierte Medikamente bei neuropathischen und anderen Schmerzen; inkludiert Fibromyalgie-Subgruppenanalyse: 5 RCTs (n=445), niedrige Evidenzqualität, keine signifikante Schmerzreduktion vs. Placebo (SMD -0.21, 95% CI -0.61 bis 0.19).

10.1002/ejp.1874 View study →
S Karst et al. · 2025 · Nature Medicine
13 citations
Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial
Clear benefit RCT (Phase III, multizentrisch, placebo-kontrolliert)

Phase-III-RCT, n=820 Erwachsene mit chronischem Rückenschmerz (CLBP); VER-01 (Cannabis-Vollspektrum-Extrakt) vs. Placebo über 12 Wochen. Primärer Endpunkt erreicht: mittlere NRS-Schmerzreduktion -1,9 Punkte (MD vs. Placebo -0,6; 95%-KI -0,9 bis -0,3; p<0,001). Schlüsselsekundärendpunkt (neuropathische Schmerzkomponente): NPSI -14,4 Punkte (MD vs. Placebo -7,3; 95%-KI -13,2 bis -1,3; p=0,017). Effekte in 6-monatiger Open-Label-Extension aufrechterhalten (NRS -2,9); kein Abhängigkeitssignal.

10.1038/s41591-025-03977-0 View study →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

Umfassende SR über 79 RCTs (n=6.462) zu medizinischem Cannabis; moderate Evidenz für chronischen Schmerz (6 RCTs), neuropathischen Schmerz, MS-Spastik; NNTB=6 für 30% Schmerzreduktion; häufigste NW: Schwindel, trockener Mund, Sedierung.

10.1001/jama.2015.6358 View study →

The impediment to action advances action. — Marcus Aurelius